Chase Investment Counsel Corp purchased a new stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 17,385 shares of the biopharmaceutical company’s stock, valued at approximately $2,438,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Fiduciary Trust Co. bought a new position in shares of Alexion Pharmaceuticals in the 2nd quarter valued at $111,000. Huntington National Bank lifted its stake in shares of Alexion Pharmaceuticals by 1,084.6% in the 2nd quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock valued at $131,000 after acquiring an additional 987 shares during the last quarter. Dupont Capital Management Corp bought a new position in shares of Alexion Pharmaceuticals in the 3rd quarter valued at $156,000. BT Investment Management Ltd bought a new position in shares of Alexion Pharmaceuticals in the 3rd quarter valued at $165,000. Finally, Penserra Capital Management LLC lifted its stake in shares of Alexion Pharmaceuticals by 13.0% in the 2nd quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock valued at $151,000 after acquiring an additional 144 shares during the last quarter. Institutional investors own 94.60% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Chase Investment Counsel Corp Purchases New Position in Alexion Pharmaceuticals, Inc. (ALXN)” was published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/chase-investment-counsel-corp-purchases-new-position-in-alexion-pharmaceuticals-inc-alxn/1693114.html.

In other Alexion Pharmaceuticals news, Director Ann M. Veneman sold 835 shares of Alexion Pharmaceuticals stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total transaction of $121,751.35. Following the completion of the transaction, the director now owns 5,480 shares in the company, valued at approximately $799,038.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Julie O’neill sold 11,160 shares of Alexion Pharmaceuticals stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $140.00, for a total value of $1,562,400.00. Following the transaction, the executive vice president now owns 26,704 shares of the company’s stock, valued at approximately $3,738,560. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 16,490 shares of company stock valued at $2,337,251. 4.35% of the stock is currently owned by company insiders.

A number of research analysts have recently commented on the company. Zacks Investment Research cut Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, November 1st. Royal Bank Of Canada increased their price target on Alexion Pharmaceuticals to $166.00 in a research note on Tuesday, October 24th. Stifel Nicolaus lowered their target price on Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating for the company in a research report on Tuesday, October 24th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $170.00 target price on shares of Alexion Pharmaceuticals in a research report on Monday, October 23rd. Finally, Leerink Swann reaffirmed a “buy” rating and set a $182.00 target price on shares of Alexion Pharmaceuticals in a research report on Monday, September 25th. Six investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the company. Alexion Pharmaceuticals currently has an average rating of “Buy” and an average target price of $154.01.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) traded down $0.57 on Friday, hitting $115.80. The stock had a trading volume of 400,964 shares, compared to its average volume of 2,285,786. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.51 and a current ratio of 2.96. The firm has a market cap of $25,779.23, a P/E ratio of 23.60, a PEG ratio of 1.27 and a beta of 1.22. Alexion Pharmaceuticals, Inc. has a 12 month low of $96.18 and a 12 month high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.12. The company had revenue of $859.00 million during the quarter, compared to the consensus estimate of $864.34 million. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The firm’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period last year, the business posted $1.23 EPS. equities research analysts predict that Alexion Pharmaceuticals, Inc. will post 4.81 earnings per share for the current fiscal year.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.